

Notice of Allowability

Application No.	Applicant(s)
10/042,703	SATO ET AL.
Examiner	Art Unit
Jezia Riley	1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. This communication is responsive to Amdt filed 11/13/03.
2. The allowed claim(s) is/are 5,6,8 and 9.
3. The drawings filed on _____ are accepted by the Examiner.
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) All
 - b) Some*
 - c) None of the:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
 - (a) The translation of the foreign language provisional application has been received.
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. **THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**


7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
8. CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) hereto or 2) to Paper No. _____.
 - (b) including changes required by the proposed drawing correction filed _____, which has been approved by the Examiner.
 - (c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No. _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).

9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- 1 Notice of References Cited (PTO-892)
- 2 Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3 Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No. _____
- 4 Examiner's Comment Regarding Requirement for Deposit
of Biological Material
- 5 Notice of Informal Patent Application (PTO-152)
- 6 Interview Summary (PTO-413), Paper No. _____.
- 7 Examiner's Amendment/Comment
- 8 Examiner's Statement of Reasons for Allowance
- 9 Other


JEZIA RILEY
PRIMARY EXAMINER

ALLOWED CLAIMS/ TJ

5. (currently amended) The element of ~~claim 3~~ claim 8, wherein the alkyne group is attached to the terminal of the nucleotide derivative or the analogue oligonucleotide, polynucleotide, or peptide-nucleotide via a linking group.
6. (currently amended) The element of ~~claim 3~~ claim 8, wherein the alkyne group is derived from one selected from the group consisting of acetylene, methylacetylene, 1-butyne, 1-pentyne, 1-hexyne, 1-heptyne, 1-octyne, 1-nonyne, and 1-decine.
8. (new) An element comprising a solid carrier and a group of oligonucleotides, polynucleotides, or peptide-nucleotides which are fixed to the solid carrier, in which the solid carrier is covered with a silver metal film or a copper metal film, the oligonucleotide, polynucleotide, or peptide-nucleotide has an alkyne chain, and the alkyne chain is directly attached to the silver metal film or a copper metal film on the solid carrier.
9. (new) A method of producing the element of claim 8, which comprises the steps of : preparing a group of oligonucleotides, polynucleotides, or peptide-nucleotides having an alkyne chain at terminals thereof and a solid carrier covered with a silver metal film or a copper metal film; and bringing the group of oligonucleotides, polynucleotides, or peptide-nucleotides having an alkyne chain into contact with the silver metal film or copper metal film of the solid carrier in a liquid phase.